<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; CEO</title>
	<atom:link href="http://www.tapanray.in/tag/ceo/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Create Purpose-Driven-Brands To Win Marketing Warfare In The New Reality</title>
		<link>http://www.tapanray.in/create-purpose-driven-brands-to-win-marketing-warfare-in-the-new-reality/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=create-purpose-driven-brands-to-win-marketing-warfare-in-the-new-reality</link>
		<comments>http://www.tapanray.in/create-purpose-driven-brands-to-win-marketing-warfare-in-the-new-reality/#comments</comments>
		<pubDate>Mon, 05 Oct 2020 00:00:34 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[consumers]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[Creating]]></category>
		<category><![CDATA[customers]]></category>
		<category><![CDATA[democratize]]></category>
		<category><![CDATA[driven]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[environment]]></category>
		<category><![CDATA[Generation]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Internet]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Millennial]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[new reality]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[people]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[purpose]]></category>
		<category><![CDATA[purpose-driven-brands]]></category>
		<category><![CDATA[rationale]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[redefinition]]></category>
		<category><![CDATA[Relevance]]></category>
		<category><![CDATA[society]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[warfare]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10286</guid>
		<description><![CDATA[As we navigate through the Covid days, the hope of somehow getting back to the pre-pandemic normal still lingers – notwithstanding a host of uncertainties in its way. The longing is driven by the hype of availability of scientifically proven, safe and &#8230; <a href="http://www.tapanray.in/create-purpose-driven-brands-to-win-marketing-warfare-in-the-new-reality/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/create-purpose-driven-brands-to-win-marketing-warfare-in-the-new-reality/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>While Pharma Leadership Change This Atypical Skill Counts</title>
		<link>http://www.tapanray.in/while-pharma-leadership-change-this-atypical-skill-counts/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=while-pharma-leadership-change-this-atypical-skill-counts</link>
		<comments>http://www.tapanray.in/while-pharma-leadership-change-this-atypical-skill-counts/#comments</comments>
		<pubDate>Mon, 01 Jul 2019 00:00:02 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Atypical]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[demand]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[digital first]]></category>
		<category><![CDATA[hardware]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[leaders]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Promotion]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[skill]]></category>
		<category><![CDATA[software]]></category>
		<category><![CDATA[Space]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[touchpoint]]></category>
		<category><![CDATA[transformation]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9613</guid>
		<description><![CDATA[Effective September 01, 2019, the global pharma major Sanofi will have a new CEO, as the present CEO retires attaining his retirement age of 65 years. This appears to be a mandatory announcement from the company, as is required during the &#8230; <a href="http://www.tapanray.in/while-pharma-leadership-change-this-atypical-skill-counts/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/while-pharma-leadership-change-this-atypical-skill-counts/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Why Many Successful CEOs Don’t Want to Retire &#8211; in Pharma Too?</title>
		<link>http://www.tapanray.in/why-many-successful-ceos-dont-want-to-retire-in-pharma-too/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=why-many-successful-ceos-dont-want-to-retire-in-pharma-too</link>
		<comments>http://www.tapanray.in/why-many-successful-ceos-dont-want-to-retire-in-pharma-too/#comments</comments>
		<pubDate>Mon, 12 Nov 2018 00:00:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[70]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Aditya]]></category>
		<category><![CDATA[Aging]]></category>
		<category><![CDATA[alkem]]></category>
		<category><![CDATA[Bank]]></category>
		<category><![CDATA[Basudeo]]></category>
		<category><![CDATA[cadila]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[Frazier]]></category>
		<category><![CDATA[GE]]></category>
		<category><![CDATA[HDFC]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[ITC]]></category>
		<category><![CDATA[Jack]]></category>
		<category><![CDATA[Kenneth]]></category>
		<category><![CDATA[L&T]]></category>
		<category><![CDATA[listed]]></category>
		<category><![CDATA[mandatory]]></category>
		<category><![CDATA[MD]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Miles]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Naik]]></category>
		<category><![CDATA[Narain]]></category>
		<category><![CDATA[Pankaj]]></category>
		<category><![CDATA[Patel]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[publicly]]></category>
		<category><![CDATA[Puri]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[RBI]]></category>
		<category><![CDATA[retire]]></category>
		<category><![CDATA[retirement]]></category>
		<category><![CDATA[Singh]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Welsh]]></category>
		<category><![CDATA[white]]></category>
		<category><![CDATA[years]]></category>
		<category><![CDATA[Yogeshwar]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9256</guid>
		<description><![CDATA[“On Eve of Retirement, Jack Welch Decides to Stick Around GE a Bit,” reported the Wall Street Journal (WSJ) on October 23, 2000. Nevertheless, even the legendary Jack Welsh was made no exception to GE’s mandatory retirement policy for the &#8230; <a href="http://www.tapanray.in/why-many-successful-ceos-dont-want-to-retire-in-pharma-too/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/why-many-successful-ceos-dont-want-to-retire-in-pharma-too/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Holistic Disease Treatment Solution: Critical For Pharma Success</title>
		<link>http://www.tapanray.in/holistic-disease-treatment-solution-critical-for-pharma-success/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=holistic-disease-treatment-solution-critical-for-pharma-success</link>
		<comments>http://www.tapanray.in/holistic-disease-treatment-solution-critical-for-pharma-success/#comments</comments>
		<pubDate>Mon, 29 Oct 2018 00:00:34 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Albert Bourla]]></category>
		<category><![CDATA[Apple]]></category>
		<category><![CDATA[CDO]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[Chart]]></category>
		<category><![CDATA[Chief]]></category>
		<category><![CDATA[critical]]></category>
		<category><![CDATA[diagnosis]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[flow]]></category>
		<category><![CDATA[holistic]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Officer]]></category>
		<category><![CDATA[Onduo]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Points]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[solution]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[touch]]></category>
		<category><![CDATA[treatment]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9238</guid>
		<description><![CDATA[The speculation over quite some time has ended now. The most important C-suite office of the world’s top pharma company will find a brand-new occupant at the dawn of a brand-new year, on January 01, 2019. Albert Bourla will now be on &#8230; <a href="http://www.tapanray.in/holistic-disease-treatment-solution-critical-for-pharma-success/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/holistic-disease-treatment-solution-critical-for-pharma-success/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Trees Die From The Top: Apt For Pharma Leadership Too?</title>
		<link>http://www.tapanray.in/trees-die-from-the-top-apt-for-pharma-leadership-too/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=trees-die-from-the-top-apt-for-pharma-leadership-too</link>
		<comments>http://www.tapanray.in/trees-die-from-the-top-apt-for-pharma-leadership-too/#comments</comments>
		<pubDate>Mon, 22 Oct 2018 00:00:17 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[appraisal]]></category>
		<category><![CDATA[apt]]></category>
		<category><![CDATA[behavior]]></category>
		<category><![CDATA[behavioral]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[Compliance]]></category>
		<category><![CDATA[dies]]></category>
		<category><![CDATA[Drucker]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[From]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[measurement]]></category>
		<category><![CDATA[metric]]></category>
		<category><![CDATA[Narasimhan]]></category>
		<category><![CDATA[Non]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[performance]]></category>
		<category><![CDATA[Peter]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[senior]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[top]]></category>
		<category><![CDATA[Tree]]></category>
		<category><![CDATA[Vas]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9229</guid>
		<description><![CDATA[The Management Guru of all-time &#8211; Peter F. Drucker once said: &#8220;The spirit of an organization is created from the top… If an organization is great in spirit, it is because the spirit of its top people is great.” As &#8230; <a href="http://www.tapanray.in/trees-die-from-the-top-apt-for-pharma-leadership-too/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/trees-die-from-the-top-apt-for-pharma-leadership-too/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Innovation and Pharma M&amp;As: A Recent Perspective</title>
		<link>http://www.tapanray.in/drug-innovation-and-pharma-mas-a-recent-perspective/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-innovation-and-pharma-mas-a-recent-perspective</link>
		<comments>http://www.tapanray.in/drug-innovation-and-pharma-mas-a-recent-perspective/#comments</comments>
		<pubDate>Mon, 04 Jun 2018 00:00:46 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[acquisition]]></category>
		<category><![CDATA[blockbuster]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[critical]]></category>
		<category><![CDATA[deal]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[hefty]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[merger]]></category>
		<category><![CDATA[objectives]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8949</guid>
		<description><![CDATA[The 21st CEO Survey 2018 of PwC highlights a curious contradiction. This is based on what the Global Pharma Chief Executive Officers (CEOs) had articulated regarding their business outlook for 2018 and beyond. The report says: Despite highly publicized hand &#8230; <a href="http://www.tapanray.in/drug-innovation-and-pharma-mas-a-recent-perspective/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-innovation-and-pharma-mas-a-recent-perspective/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Stakeholder Sentiment: Back to Square One?</title>
		<link>http://www.tapanray.in/pharma-stakeholder-sentiment-back-to-square-one/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-stakeholder-sentiment-back-to-square-one</link>
		<comments>http://www.tapanray.in/pharma-stakeholder-sentiment-back-to-square-one/#comments</comments>
		<pubDate>Mon, 28 May 2018 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[Dekkers]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[Drucker]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[George]]></category>
		<category><![CDATA[guru]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Marjin]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[maximizing]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[non-profit]]></category>
		<category><![CDATA[one]]></category>
		<category><![CDATA[Peter]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[purpose]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sentiment]]></category>
		<category><![CDATA[socializing]]></category>
		<category><![CDATA[square]]></category>
		<category><![CDATA[stakeholder]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8965</guid>
		<description><![CDATA[Is it fair to push out the core purpose of an important process, or rather a mission, unfairly? Whether we like it or not, it happened that way, over a period of time. Way back on December 01, 1950, George W. &#8230; <a href="http://www.tapanray.in/pharma-stakeholder-sentiment-back-to-square-one/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-stakeholder-sentiment-back-to-square-one/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Organic and Inorganic Growth Strategy For Sustainable Business Excellence</title>
		<link>http://www.tapanray.in/organic-and-inorganic-growth-strategy-for-sustainable-business-excellence/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=organic-and-inorganic-growth-strategy-for-sustainable-business-excellence</link>
		<comments>http://www.tapanray.in/organic-and-inorganic-growth-strategy-for-sustainable-business-excellence/#comments</comments>
		<pubDate>Mon, 30 Apr 2018 00:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inorganic]]></category>
		<category><![CDATA[leader]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[Novo Nordisk]]></category>
		<category><![CDATA[organic]]></category>
		<category><![CDATA[performance]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[sustainable]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8936</guid>
		<description><![CDATA[For an enthusiast, witnessing any organization growing consistently, is indeed exhilarating. This becomes even more interesting at a time when challenges and frequent surprises in the business environment become a new normal. A robust short, medium and long growth strategy &#8230; <a href="http://www.tapanray.in/organic-and-inorganic-growth-strategy-for-sustainable-business-excellence/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/organic-and-inorganic-growth-strategy-for-sustainable-business-excellence/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Moving Beyond The Pill: No Longer An Option</title>
		<link>http://www.tapanray.in/moving-beyond-the-pill-no-longer-an-option-2/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=moving-beyond-the-pill-no-longer-an-option-2</link>
		<comments>http://www.tapanray.in/moving-beyond-the-pill-no-longer-an-option-2/#comments</comments>
		<pubDate>Sun, 12 Nov 2017 23:54:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[beyond]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[Entresto]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[measurable]]></category>
		<category><![CDATA[moving]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[option]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pill]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[treatment]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8520</guid>
		<description><![CDATA[Many of us would prefer to live, as long as possible, in the comfort zones of old paradigms, hoping to succeed in the same way as we had succeeded in the past. But the wheel of time keeps moving, triggering &#8230; <a href="http://www.tapanray.in/moving-beyond-the-pill-no-longer-an-option-2/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/moving-beyond-the-pill-no-longer-an-option-2/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Sine Qua Non to Pharma Success in Digitized World</title>
		<link>http://www.tapanray.in/a-sine-qua-non-to-pharma-success-in-digitized-world/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-sine-qua-non-to-pharma-success-in-digitized-world</link>
		<comments>http://www.tapanray.in/a-sine-qua-non-to-pharma-success-in-digitized-world/#comments</comments>
		<pubDate>Mon, 16 Oct 2017 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[diagnosis]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[digitization]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[genome]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[personalization]]></category>
		<category><![CDATA[Pharma. Success.Digitized. World]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sine Qua Non]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8472</guid>
		<description><![CDATA[A wind of change is now blowing at an accelerated speed &#8211; encompassing virtually anything, across the world, including India, with a varying degree, though. It leaves a profound impact on the day to day lives of many, including almost &#8230; <a href="http://www.tapanray.in/a-sine-qua-non-to-pharma-success-in-digitized-world/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-sine-qua-non-to-pharma-success-in-digitized-world/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
